Chipscreen(SH:688321) 智通财经网·2026-01-26 11:23Core Viewpoint - Microchip Biotech (688321.SH) is expected to achieve a net profit of approximately 53.46 million yuan for the year 2025, marking an increase of about 168.03 million yuan compared to the same period last year, thus turning a profit [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 53.46 million yuan for 2025, representing a year-on-year increase of about 168.03 million yuan, indicating a turnaround from loss to profit [1] - The company's revenue is expected to grow significantly, driven by the sales of its product, Siglecatin Sodium, which has seen a year-on-year increase of around 123% due to its unique clinical value and effective commercialization strategies [1] Group 2: Product Development and Market Recognition - The product, Sidabamine, has gained recognition in the market and support from the National Healthcare Security Administration, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Directory in January 2025 [1] - The inclusion of Sidabamine in the latest version of the National Medical Insurance Directory under regular Class B management in December 2025 is expected to contribute to a year-on-year revenue growth of approximately 16% [1]